• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cessatech

19.55 DKK

+6.83 %

Less than 1K followers

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+6.83 %
+16.37 %
+11.84 %
+22.49 %
+60.77 %
+49.24 %
+918.23 %
+24.76 %
+81.28 %

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.

Read more
Market cap
363.17M DKK
Turnover
1.04M DKK
Revenue
5.72M
EBIT %
-261.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
28/8
2026

Interim report Q2'26

26/11
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release18 hours ago

Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children

Cessatech
Regulatory press release5/28/2026, 6:30 AM

Cessatech: First Quarter Report Q1-2026

Cessatech
Regulatory press release3/30/2026, 9:45 AM

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/13/2026, 7:30 AM

Cessatech convenes its Annual General Meeting

Cessatech
Regulatory press release2/27/2026, 7:30 AM

Cessatech A/S Announces Financial Results for the Full Year 2025

Cessatech
Regulatory press release2/2/2026, 7:00 AM

Cessatech: Welcome to the first quarter of 2026

Cessatech
Regulatory press release11/13/2025, 7:30 AM

Cessatech: Third Quarter Report Q3-2025

Cessatech
Regulatory press release10/31/2025, 12:00 PM

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Cessatech
Regulatory press release8/21/2025, 6:30 AM

Cessatech: Second Quarter Report Q2-2025

Cessatech
Regulatory press release8/14/2025, 4:00 PM

Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children

Cessatech
Press release6/27/2025, 11:31 AM

Cessatech Q&A - June company presentation

Cessatech
Regulatory press release6/19/2025, 11:30 AM

Cessatech strengthens Executive Management with the promotion of Martin Juhl

Cessatech
Regulatory press release6/11/2025, 12:15 PM

Cessatech announce completion of the directed issue of shares

Cessatech
Regulatory press release5/28/2025, 8:30 PM

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Cessatech
Regulatory press release5/28/2025, 3:30 PM

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Cessatech
Regulatory press release5/28/2025, 3:15 PM

Cessatech announces positive top-line results from its final CT001 Study 0202

Cessatech
Regulatory press release5/15/2025, 6:30 AM

Cessatech: First Quarter Report Q1-2025

Cessatech
Regulatory press release4/30/2025, 1:45 PM

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Cessatech
Regulatory press release3/28/2025, 10:30 AM

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech
Regulatory press release3/12/2025, 7:30 AM

Cessatech: Annual General Meeting - 28 March 2025

Cessatech